US2018066266A1PendingUtilityA1

Eml4-alk fusion gene

Assignee: ASTELLAS PHARMA INCPriority: Oct 11, 2006Filed: Nov 13, 2017Published: Mar 8, 2018
Est. expiryOct 11, 2026(~0.2 yrs left)· nominal 20-yr term from priority
A61P 35/00C07K 2319/00A61P 43/00A61K 31/506C12N 2310/14C07K 14/47C12N 15/1137C12Q 1/485C12Q 1/6886C12N 9/1205
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene

Claims

exact text as granted — not AI-modified
1 . A double-stranded nucleic acid having an inhibitory activity against the expression of a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2 or 7 and having a kinase activity, wherein a double-stranded portion is designed on the basis of bases at positions selected from a group consisting of (1) 1743 to 1761, (2) 1744 to 1762, (3) 1750 to 1768, (4) 1753 to 1771, (5) 1756 to 1774, and (6) 1757 to 1775 in SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2018066266A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.